News PureTech licenses 'bacterial cocktail' to boost cancer immun... PureTech Health is to develop a combination of a microbiome treatment with checkpoint inhibitor immunotherapy to enhance the effect of the cancer drugs.
News Novartis, BMS, Janssen unveil R&D deals Companies announce eye-catching R&D plans ahead of conference.
Articles JP Morgan Healthcare Conference: 7 trends to watch Taking place this week in San Francisco, the annual JP Morgan Healthcare Conference has become the agenda-setting meeting for pharma and biotech.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.